Lymphopenia News and Research

RSS

Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.

Study identifies immune profile of people with severe COVID-19

A team of researchers at Georgetown University Medical Center, USA, investigated how SARS-CoV-2 affects the immune system’s response during and after infection and contributes to the severity of COVID-19.

22 Feb 2021

What are the changes in the physical phenotype of blood cells in COVID-19?

While primarily a respiratory illness, there are distinctive alterations in the type and number of blood cells in COVID-19. A new study by a team of researchers in Germany describes the nature of these changes.

16 Feb 2021

Hematological findings in Amazonian patients with COVID-19

To discriminate between patients with severe and non-severe COVID-19 quickly, researchers from Peru looked for prognostic signatures in the blood samples of COVID-19 patients. Virgilio E. Failoc-Rojas et al. examined laboratory results and clinical prognosis of COVID-19 patients from a hospital in the Peruvian Amazon.

3 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

SARS-CoV-2-specific T cells are key players in decreasing COVID-19 mortality

A recent US study, currently available on medRxiv preprint server, supports a beneficial rather than immunopathologic role for effector T-cells during serious infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –

31 Jan 2021

High factor V levels linked to lymphopenia and weakened immunity in severe COVID-19

A new study suggests that factor V, a coagulation factor, is upregulated in a range of white blood cells in severe COVID-19. This increase is linked to the observed coagulopathy, lymphopenia and suppression of adaptive immunity in such patients.

21 Jan 2021

SARS-CoV-2 RNA in blood serum could predict COVID-19 mortality

Researchers find that the presence of SARS-CoV-2's genetic material in the serum of positive patients could be a sturdy biomarker for predicting COVID-19-related mortality.

18 Jan 2021

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.

26 Nov 2020

SARS-CoV-2-specific IgM / IgG responses accurately predict COVID-19 outcome

Researchers from the Huazhong University of Science and Technology and Shanghai Jiao Tong University, China, recently built a proteome microarray with 20 out of the 28 predicted SARS-CoV-2 proteins to help understand IgM/IgG responses specific to SARS-CoV-2.

17 Nov 2020

Preliminary analysis of photon therapy treatment group 1 shows no significant differences between arms

A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM).

27 Oct 2020

Characterization of prognostic markers to predict COVID-19 severity

A team of scientists from the United Kingdom has revealed that markers of endothelial cell injury are associated with severe and fatal outcome of coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.

14 Oct 2020

Pathways contributing to hypercoagulability in severe SARS‐CoV‐2 patients

In a study by researchers explored the possible mechanisms of the clotting disorder, focusing on the role of hypoxia-related activation of coagulation factors; cytokine storm, activation of neutrophils, and the release of neutrophil extracellular traps.

11 Oct 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

LOX-1-immature neutrophils may help identify COVID-19 patients at risk of thrombosis complication

To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.

17 Sep 2020

D-dimer - A sensitive novel biomarker of COVID-19 mortality

Now, a new study published on the preprint server medRxiv* reports the use of D-dimer in predicting the risk of mortality in COVID-19.

7 Sep 2020

Exponential rise in COVID-19 hospitalization risk with age due to waning T cell immunity

The age-related increase in the risk of severe disease and death from COVID-19 mirrors earlier patterns seen with infections. Such trends may help understand the mechanisms underlying the clinical feature. A recent study published in the preprint server medRxiv* in August 2020 shows the effect of age and sex on COVID-19 hospitalization rates in the USA and helps understand how immune function is involved in this pandemic.

2 Sep 2020

SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19

A new study by a large team of Spanish researchers and published on the preprint server medRxiv* in August 2020 reports that the presence of viral RNA in the blood is a useful marker of impending acute disease and can help triage COVID-19 disease patients who will require hospital care.

1 Sep 2020

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

27 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020